When and How Long Is a Bisphosphonate Drug Holiday?
At a Glance
A bisphosphonate drug holiday may be considered after about 5 years of oral treatment or 3 years of intravenous treatment when fracture risk is no longer high. The break is individualized and monitored, and it does not apply to denosumab.
In this answer
3 sections
A “drug holiday” from bisphosphonates is a temporary, carefully monitored break from your osteoporosis medication. Because bisphosphonates (such as oral alendronate or intravenous zoledronic acid) accumulate and stay in your bones, they can continue to preserve bone strength and reduce fracture risk even after you stop taking them [1][2].
Important Safety Warning: A drug holiday applies only to bisphosphonates. It does NOT apply to denosumab (Prolia). Stopping or delaying denosumab without starting another bone medication can cause rapid bone loss and multiple spine fractures. Never stop denosumab without a transition plan from your doctor.
According to the 2020 American Association of Clinical Endocrinology (AACE) guidelines, a drug holiday is typically considered after 5 years of oral bisphosphonates or 3 years of intravenous (IV) bisphosphonates, provided your fracture risk is no longer high [3][4]. The holiday itself is highly individualized—often lasting up to about 5 years, but it is reassessed regularly [5].
When Can You Take a Drug Holiday?
Whether and when you can take a drug holiday depends entirely on your personal risk of breaking a bone. It is not an automatic pause that happens at a fixed time [1]. Your doctor will evaluate your history, including any fragility fractures (broken bones from a standing height), falls, and results from a DEXA scan (a low-dose X-ray that measures bone mineral density) and a FRAX score (a tool that estimates your percentage risk of breaking a bone in the next 10 years).
These are examples of how the AACE guidelines categorize risk, rather than a self-diagnosis checklist:
- Low to Moderate Risk: If you have not had prior hip or spine fractures and your hip T-score (a number comparing your bone density to a healthy young adult) is above -2.5, your doctor may suggest a holiday after 5 years of oral treatment or 3 years of IV treatment [4][3].
- High Risk: If your fracture risk remains high—for example, due to age, glucocorticoid (steroid) use, or prior major fractures—you may need to defer a holiday and continue oral bisphosphonates for up to 10 years, or IV bisphosphonates for up to 6 years [1][4].
- Very High Risk: If you have very high-risk features, a holiday may be deferred for an extended period or you may be switched to a different medication. Very high-risk features include a recent fracture, breaking a bone while on medication, a T-score below -3.0, a high risk of falling, or a very high FRAX probability [3][6].
How Long Does the Holiday Last and How is it Monitored?
There is no single, universally mandated length for a drug holiday [1]. The duration is highly individualized, often lasting up to about 5 years, depending on the specific drug you were taking and how your body responds [5]. For example, the effects of oral risedronate may wear off faster than alendronate, while zoledronic acid (an IV medication) may provide longer-lasting protection [7][5].
During your holiday, you will still need periodic monitoring [1]. This is not a time to forget about bone health.
- Follow-up Scans: Your doctor will order periodic DEXA scans. They look for significant bone loss that exceeds the measurement error of the machine [1].
- Blood Tests (Optional): Your doctor might test your blood for bone turnover markers (like CTX or PINP). These are optional supporting measures—not standalone rules—that give clues about how fast your bone is breaking down and rebuilding [8][9].
What to do during a holiday: Even while off medication, you should continue clinician-recommended calcium and vitamin D intake, do weight-bearing and resistance exercises, practice fall prevention, and avoid smoking and excessive alcohol.
When Does a Holiday End?
A drug holiday is a pause, not a permanent stop. Your doctor will recommend restarting or changing your osteoporosis treatment if:
- You experience a new fracture, or experience sudden severe back pain or height loss [5].
- Your bone density drops significantly, for example, if your hip T-score falls below -2.5 (though this is just an example guideline, not a rigid rule) [5].
- Your clinical risk of falling or breaking a bone increases due to new health conditions, like needing long-term steroid therapy [5].
- Your bone turnover markers rise significantly in conjunction with other clinical signs that the protective effect has worn off [8][9].
A drug holiday aims to balance the benefits of preserving bone strength with the need to minimize the rare side effects of long-term bisphosphonate use, such as atypical thigh fractures (watch for new, persistent thigh or groin pain) and osteonecrosis of the jaw (a rare healing problem in the jawbone) [10]. Always discuss your specific timeline and symptoms with your healthcare team before making any changes.
Common questions in this guide
What is a bisphosphonate drug holiday?
When can I take a drug holiday from bisphosphonates?
How long does a bisphosphonate drug holiday last?
How will my doctor monitor me during a bisphosphonate holiday?
When should I restart osteoporosis medicine after a drug holiday?
Can I take a drug holiday from Prolia or denosumab?
What can I do to protect my bones during a bisphosphonate holiday?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on osteoporosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my current T-scores, FRAX score, and fracture history, am I a candidate for a drug holiday now, or should we defer it?
- 2.What specific factors in my medical history place me in a low, high, or very high-risk category according to the guidelines?
- 3.If we pause medication, what is the plan for monitoring my bone density, and what specific changes would prompt us to restart or change my treatment?
- 4.If a holiday isn't right for me, what are my alternative treatment options?
References
References (10)
- 1
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
Adler RA, El-Hajj Fuleihan G, Bauer DC, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2016; (31(1)):16-35 doi:10.1002/jbmr.2708.
PMID: 26350171 - 2
Diagnosis and Management of Osteoporosis.
Jeremiah MP, Unwin BK, Greenawald MH, Casiano VE
American family physician 2015; (92(4)):261-8.
PMID: 26280231 - 3
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.
Camacho PM, Petak SM, Binkley N, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(Suppl 1)):1-46 doi:10.4158/GL-2020-0524SUPPL.
PMID: 32427503 - 4
Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?
Bauer DC, Abrahamsen B
Current osteoporosis reports 2021; (19(2)):182-188 doi:10.1007/s11914-021-00660-4.
PMID: 33528743 - 5
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
Anagnostis P, Paschou SA, Mintziori G, et al.
Maturitas 2017; (101()):23-30 doi:10.1016/j.maturitas.2017.04.008.
PMID: 28539165 - 6
Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.
McClung MR, Betah D, Deignan C, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2023; (29(9)):716-722 doi:10.1016/j.eprac.2023.06.011.
PMID: 37406858 - 7
Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials.
Kim TY, Bauer DC, McNabb BL, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2019; (34(5)):810-816 doi:10.1002/jbmr.3654.
PMID: 30536713 - 8
Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
Naylor KE, McCloskey EV, Jacques RM, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2019; (30(4)):917-922 doi:10.1007/s00198-018-04823-5.
PMID: 30613868 - 9
Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?
Statham L, Abdy S, Aspray TJ
Drugs in context 2020; (9()) doi:10.7573/dic.2020-1-3.
PMID: 32426015 - 10
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM, Geiger EJ, Eastell R, et al.
The New England journal of medicine 2020; (383(8)):743-753 doi:10.1056/NEJMoa1916525.
PMID: 32813950
This page is for informational purposes only and does not constitute medical advice. Your clinician should decide whether a bisphosphonate holiday is appropriate, and you should never stop or delay denosumab without a transition plan.